C3 and Cirrhosis: This prompted their testing in a phase 1 safety study of autologous macrophage therapy in cirrhosis, which demonstrated safety and, in this uncontrolled study, improvements in non-invasive tests of hepatic fibrosis in some participants after treatment, including transient elastography and serum biomarkers (ELF, PRO-C3 and C3M)19.